Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kerr

Showing results (231-240 of 315) with videos related to

Pageof 32
Sort By:
International Journal of Cancer|July 16, 2021
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancerKatie Watts, Christopher Wills, Ayman Madi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
British Journal of Cancer|August 8, 2019
Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
Oncogenesis|February 21, 2019
An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistanceNingning Li, Roya Babaei-Jadidi, Federica Lorenzi, et al.
British Journal of Cancer|September 25, 2019
Correction: Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
ESMO Open|November 21, 2020
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancerChristian H Bergsland, Jarle Bruun, Marianne G Guren, et al.
Cancer Research|July 18, 2023
GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent MannerZijing Wang, Nan Zhang, Miao Zhang, et al.
BMC Cancer|July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphomaStephen W Booth, Toby A Eyre, John Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2011
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinomaJ Randolph Hecht, Tanja Trarbach, John D Hainsworth, et al.
Diabetes Care|March 12, 2025
Quantifying Environmental Waste From Diabetes Devices in the U.STiffany Tian, Cindy N Ho, Alessandra T Ayers, et al.
Pageof 32

Showing results (231-240 of 315) with videos related to

Sort By:
Pageof 32
International Journal of Cancer|July 16, 2021
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancerKatie Watts, Christopher Wills, Ayman Madi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
British Journal of Cancer|August 8, 2019
Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
Oncogenesis|February 21, 2019
An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistanceNingning Li, Roya Babaei-Jadidi, Federica Lorenzi, et al.
British Journal of Cancer|September 25, 2019
Correction: Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
ESMO Open|November 21, 2020
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancerChristian H Bergsland, Jarle Bruun, Marianne G Guren, et al.
Cancer Research|July 18, 2023
GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent MannerZijing Wang, Nan Zhang, Miao Zhang, et al.
BMC Cancer|July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphomaStephen W Booth, Toby A Eyre, John Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2011
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinomaJ Randolph Hecht, Tanja Trarbach, John D Hainsworth, et al.
Diabetes Care|March 12, 2025
Quantifying Environmental Waste From Diabetes Devices in the U.STiffany Tian, Cindy N Ho, Alessandra T Ayers, et al.
Pageof 32